A Phase 1/2 interventional study of Pegozafermin and Placebo in NASH, sponsored by 89bio, Inc.. Completed at 26 sites in 2 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by 89bio, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 162nd largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 14 in phase 1/2, and was the 303rd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 62 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
89bio, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
89bio, Inc. has 3 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high risk of NASH, including a pre-defined number of participants with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled.
Part 2: This is a multi-center, open label evaluation of pegozafermin at 27 mg administered weekly for 20 weeks in participants with biopsy-proven NASH (NAS ≥4, fibrosis stage F2 or F3).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered 3 mg of pegozafermin QW, via subcutaneous (SC) injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered 9 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered 18 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered 18 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered 36 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
Drug: Pegozafermin
Participants were administered placebo matching to pegozafermin QW or Q2W, via SC injection, starting on Day 1 through Day 85.
Other: Placebo
Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 134.
Drug: Pegozafermin
Subcutaneous injection
Also known as: BIO89-100
Subcutaneous injection
Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Up to 113 days
Part 2: Number of Participants With TEAEs
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Up to 162 days
Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin
Time frame: Predose and up to 168 hours postdose on Day 29
Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin
Time frame: Predose and up to 168 hours postdose on Day 29
Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin
Time frame: Predose and up to 168 hours postdose on Day 29
Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin
Time frame: Predose and up to 168 hours postdose on Day 29
Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranges from of 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH Clinical Research Network (CRN) fibrosis score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Day 141
Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin
Number of participants with anti-pegozafermin antibodies (ADA) with status as ADA positive has been reported.
Time frame: Up to 113 days
Parts 1 and 2: Percent Change From Baseline in Body Weight
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM).
Time frame: Part 1: Baseline, Day 85; Part 2: Baseline, Day 141
Parts 1 and 2: Percent Change From Baseline in Triglycerides, High Density Lipoprotein (HDL) Cholesterol (c), Non-HDLc, LDLc, Hemoglobin (HbA1C), Alanine Transaminase, Aspartate Aminotransferase, N-terminal Propeptide of Type III Collagen (Pro-C3)
LS Mean was calculated using MMRM.
Time frame: Part 1: Baseline, Day 92; Part 2: Baseline, Day 141
Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92
LS Mean was calculated using MMRM. HOMA-IR value was calculated by multiplying fasting Glucose (mg/dL) with fasting Insulin (uIU/ml) and then dividing by 405.
Time frame: Baseline, Day 92
Part 1: Percent Change From Baseline in Adiponectin at Day 92
LS Mean was calculated using MMRM.
Time frame: Baseline, Day 92
Part 1: Percent Change From Baseline in Free Fatty Acid at Day 92
LS Mean was calculated using MMRM.
Time frame: Baseline, Day 92
Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50
LS Mean was calculated using MMRM. Adipo-IR was derived from fasting insulin and free fatty acid.
Time frame: Baseline, Day 50
Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
LS Mean was calculated using MMRM.
Time frame: Part 1: Baseline, Day 92; Part 2: Baseline, Day 141
Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH
Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. Worsening of NASH was defined as increase ≥1 point in NAS for ballooning or inflammation. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Day 141
Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis
Resolution of NASH included the total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1). Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
Time frame: Day 141
| Milestone | Part 1: Pegozafermin 3 Milligrams (mg) Weekly (QW) | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Every 2 Weeks (Q2W) | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 12 | 11 | 10 | 14 | 9 | 19 | 20 |
| Received 1 dose of study drug | 6 | 12 | 11 | 10 | 14 | 9 | 19 | 20 |
| Safety analysis set | 7 | 12 | 11 | 10 | 14 | 9 | 18 | 20 |
| Completed | 5 | 11 | 10 | 7 | 13 | 8 | 18 | 19 |
| Not completed | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) | 6 | 4 | 7 | 7 | 8 | 8 | 8 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Part 2: Pegozafermin 27 mg QW |
|---|---|
| Part 2: Number of Participants With TEAEs | 18 |
| ng/mL | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W |
|---|---|---|---|---|---|---|
| Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin | 103 (59 to 156) | 439 (238 to 852) | 901 (200 to 1281) | 1166 (566 to 2243) | 649 (160 to 1300) | 1674 (1300 to 2791) |
| ng*hour/mL | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W |
|---|---|---|---|---|---|---|
| Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin | 11879 (7350 to 17778) | 42576 (24394 to 70300) | 95765 (24822 to 138904) | 112632 (57880 to 231937) | 78761 (20520 to 155994) | 209436 (153404 to 287414) |
| hr | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W |
|---|---|---|---|---|---|---|
| Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin | 59.5 (47.3 to 72.0) | 48.0 (18.6 to 58.8) | 48.0 (34.7 to 72.1) | 48.1 (46.3 to 63.4) | 72.0 (47.5 to 95.2) | 48.0 (45.2 to 71.6) |
| hr | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W |
|---|---|---|---|---|---|---|
| Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin | 57.1 (54.0 to 75.3) | 46.3 (36.1 to 67.7) | 68.1 (50.8 to 114.0) | 53.0 (27.9 to 62.2) | 54.4 (45.5 to 70.4) | 53.2 (37.4 to 62.2) |
NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranges from of 0 to 8, with higher scores indicating worse disease severity. Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH Clinical Research Network (CRN) fibrosis score. NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Part 2: Pegozafermin 27 mg QW |
|---|---|
| Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis | 12 |
Number of participants with anti-pegozafermin antibodies (ADA) with status as ADA positive has been reported.
| Participants | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin | 1 | 9 | 7 | 7 | 11 | 6 | 2 |
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM).
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percent Change From Baseline in Body Weight | 1.19 ± 1.06 | 2.59 ± 0.74 | 2.47 ± 0.79 | -0.80 ± 0.86 | 2.11 ± 0.69 | 2.64 ± 0.86 | 1.38 ± 0.59 | -3.10 ± 0.83 |
LS Mean was calculated using MMRM.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| Triglycerides | -22.74 ± 11.53 | -23.95 ± 7.74 | -17.71 ± 8.20 | -27.63 ± 9.66 | -28.49 ± 8.62 | -20.71 ± 9.74 | -2.21 ± 6.23 | -25.30 ± 5.66 |
| HDLc | 18.17 ± 5.43 | 11.19 ± 3.68 | 9.20 ± 3.92 | 2.90 ± 4.50 | 20.10 ± 3.73 | 9.79 ± 4.56 | 1.96 ± 2.97 | 22.65 ± 5.58 |
| Non HDLc | -6.31 ± 6.45 | -13.87 ± 4.61 | -1.92 ± 4.74 | -16.32 ± 5.51 | -7.75 ± 4.38 | -6.34 ± 5.39 | 1.18 ± 3.56 | -17.12 ± 3.53 |
| LDLc | -6.17 ± 7.38 | -13.45 ± 5.29 | 2.59 ± 5.41 | -16.46 ± 6.34 | -5.02 ± 5.06 | -4.11 ± 6.20 | 1.15 ± 4.08 | -12.36 ± 4.80 |
| HbA1C | 7.36 ± 4.05 | 1.80 ± 2.84 | 3.05 ± 2.99 | -3.66 ± 3.42 | -1.85 ± 2.60 | 6.89 ± 3.43 | 0.61 ± 2.28 | -7.23 ± 1.66 |
| Alanine Transaminase | -16.87 ± 10.62 | -26.65 ± 6.99 | -26.73 ± 7.40 | -43.69 ± 8.55 | -18.83 ± 6.38 | -39.84 ± 8.42 | -4.18 ± 5.47 | -45.80 ± 3.86 |
| Aspartate Aminotransferase | -29.36 ± 9.47 | -19.90 ± 6.15 | -15.10 ± 6.52 | -37.88 ± 7.52 | -11.41 ± 5.63 | -25.32 ± 7.43 | -4.40 ± 4.85 | -47.28 ± 3.54 |
| Pro-C3 | -19.71 ± 14.53 | -18.79 ± 9.02 | 1.08 ± 9.38 | -27.67 ± 11.20 | -11.18 ± 8.19 | -12.76 ± 11.22 | 3.26 ± 7.02 | -19.52 ± 3.28 |
LS Mean was calculated using MMRM. HOMA-IR value was calculated by multiplying fasting Glucose (mg/dL) with fasting Insulin (uIU/ml) and then dividing by 405.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92 | 10.37 ± 51.30 | 7.40 ± 30.62 | 37.07 ± 20.87 | -41.42 ± 19.48 | -4.57 ± 15.57 | -41.11 ± 23.39 | -0.09 ± 15.72 |
LS Mean was calculated using MMRM.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Percent Change From Baseline in Adiponectin at Day 92 | 37.65 ± 14.48 | 25.46 ± 9.88 | 29.09 ± 10.47 | 60.85 ± 12.00 | 23.11 ± 9.07 | 24.14 ± 12.10 | -4.25 ± 7.80 |
LS Mean was calculated using MMRM.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Percent Change From Baseline in Free Fatty Acid at Day 92 | 28.70 ± 24.68 | 50.20 ± 21.05 | 27.08 ± 17.76 | 51.58 ± 22.08 | 43.85 ± 18.17 | 56.12 ± 20.81 | 20.91 ± 13.96 |
LS Mean was calculated using MMRM. Adipo-IR was derived from fasting insulin and free fatty acid.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W |
|---|---|---|---|---|---|---|---|
| Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50 | -6.12 ± 61.71 | 82.00 ± 59.79 | 3.28 ± 60.01 | 78.40 ± 46.41 | -25.96 ± 42.75 | -10.36 ± 50.33 | -15.82 ± 32.62 |
LS Mean was calculated using MMRM.
| Percent change | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) | -36.94 ± 11.01 | -49.62 ± 7.73 | -36.11 ± 8.14 | -60.39 ± 9.40 | -43.19 ± 6.99 | -50.39 ± 9.07 | 9.77 ± 6.04 | -64.69 ± 3.38 |
Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score. Worsening of NASH was defined as increase ≥1 point in NAS for ballooning or inflammation. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Part 2: Pegozafermin 27 mg QW |
|---|---|
| Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH | 5 |
Resolution of NASH included the total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1). Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score. NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).
| Participants | Part 2: Pegozafermin 27 mg QW |
|---|---|
| Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis | 6 |
Collected over Adverse Events were collected after dosing to end of study (up to 113 days for Part 1 and up to 162 days for Part 2).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Pegozafermin 3 mg QW | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part 1: Pegozafermin 9 mg QW | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Part 1: Pegozafermin 18 mg QW | 0/11 (0%) | 0/11 (0%) | 7/11 (63.6%) |
| Part 1: Pegozafermin 27 mg QW | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Part 1: Pegozafermin 18 mg Q2W | 0/14 (0%) | 1/14 (7.1%) | 8/14 (57.1%) |
| Part 1: Pegozafermin 36 mg Q2W | 0/9 (0%) | 1/9 (11.1%) | 8/9 (88.9%) |
| Part 1: Placebo QW or Q2W | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Part 2: Pegozafermin 27 mg QW | 0/20 (0%) | 0/20 (0%) | 18/20 (90%) |
| Event | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/7 | 0/12 | 0/11 | 0/10 | 1/14 | 1/9 | 0/18 | 0/20 |
| Event | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW |
|---|---|---|---|---|---|---|---|---|
| Increased AppetiteMetabolism and nutrition disorders | 4/7 | 2/12 | 0/11 | 2/10 | 2/14 | 0/9 | 0/18 | 0/20 |
| NauseaGastrointestinal disorders | 1/7 | 0/12 | 1/11 | 0/10 | 3/14 | 0/9 | 3/18 | 10/20 |
| DiarrhoeaGastrointestinal disorders | 1/7 | 2/12 | 0/11 | 2/10 | 1/14 | 2/9 | 4/18 | 7/20 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/7 | 0/12 | 0/11 | 1/10 | 1/14 | 0/9 | 0/18 | 0/20 |
| HeadacheNervous system disorders | 1/7 | 0/12 | 0/11 | 2/10 | 2/14 | 2/9 | 1/18 | 1/20 |
| LymphadenopathyBlood and lymphatic system disorders | 0/7 | 0/12 | 0/11 | 2/10 | 0/14 | 0/9 | 0/18 | 0/20 |
| Abdominal Pain UpperGastrointestinal disorders | 0/7 | 0/12 | 1/11 | 0/10 | 0/14 | 0/9 | 0/18 | 4/20 |
| VomitingGastrointestinal disorders | 1/7 | 1/12 | 0/11 | 0/10 | 1/14 | 0/9 | 1/18 | 4/20 |
| FatigueGeneral disorders | 1/7 | 0/12 | 0/11 | 0/10 | 0/14 | 0/9 | 0/18 | 4/20 |
| Abdominal TendernessGastrointestinal disorders | 0/7 | 2/12 | 0/11 | 0/10 | 0/14 | 0/9 | 0/18 | 0/20 |
Analysis population description: For Part 1, randomized analysis set included all randomized participants who received at least 1 dose of investigational product. For Part 2, Full analysis set included all enrolled participants who received at least 1 dose of investigational product.
| Age, Continuous(years) | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 56.13 ± 8.23 | 49.50 ± 11.45 | 51.47 ± 13.39 | 51.96 ± 9.83 | 51.22 ± 8.14 | 52.46 ± 8.73 | 52.62 ± 8.99 | 58.44 ± 9.07 | 52.97 ± 1.81 |
| Sex: Female, Male(Participants) | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 8 | 8 | 10 | 1 | 12 | 15 | 65 |
| Male | 1 | 6 | 3 | 2 | 4 | 8 | 7 | 5 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 11 | 9 | 10 | 13 | 9 | 16 | 5 | 79 |
| Not Hispanic or Latino | 0 | 1 | 2 | 0 | 1 | 0 | 3 | 15 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Pegozafermin 3 mg QW | Part 1: Pegozafermin 9 mg QW | Part 1: Pegozafermin 18 mg QW | Part 1: Pegozafermin 27 mg QW | Part 1: Pegozafermin 18 mg Q2W | Part 1: Pegozafermin 36 mg Q2W | Part 1: Placebo QW or Q2W | Part 2: Pegozafermin 27 mg QW | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 5 |
| White | 5 | 11 | 9 | 10 | 13 | 9 | 17 | 20 | 94 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jul 2019 to primary completion in Aug 2020, 12 months.
Results were first posted in Apr 2024, 3 years 7 months after primary completion.
Of 21 phase 1/2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegozafermin
Non-alcoholic Fatty Liver Disease →
89bio, Inc.